Durvalumab vs Methotrexate

Durvalumab vs Methotrexate: Overview

This comparison examines the pharmacological differences between Durvalumab and Methotrexate.

Mechanism of Action

Durvalumab: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

Methotrexate: Dihydrofolate reductase inhibitor.

Pharmacokinetics

Half-life: Durvalumab — 17 days; Methotrexate — 3-10 hours.

Chemical Properties

Molecular Formula: Methotrexate — C20H22N8O5.

Molecular Weight: Methotrexate — 454.4400 g/mol.

Type: Durvalumab — Antibody; Methotrexate — Small molecule.